Okay, thank you.
Ms. Fernandez, the TPP's chapter on intellectual property includes a number of provisions that relate to patents for pharmaceutical products, including an adjustment to the patent term for the time lost in regulatory and governmental approval procedures for such products.
To what extent is it likely that the greater protection of intellectual property for pharmaceutical products would encourage innovation in Canada and contribute to the development of new options for treating diseases affecting Canadians?